Liposomal compositions of epoxyketone-based proteasome inhibitors
Liposomal compositions comprising peptide epoxyketone compounds are described, as well as methods of making and using such liposomal compositions. These liposomal compositions enhance the therapeutic window of peptide epoxyketone compounds by improving in vivo half-life relative to non-liposomal compositions comprising peptide epoxyketone compounds, providing desirable pharmacodynamic profiles, and providing anti-tumor activity in a human tumor xenograft model, greater than or equal to non-liposomal compositions comprising peptide epoxyketone compounds. Further, experiments performed in support of the present invention demonstrated improved tolerability of liposomal compositions comprising peptide epoxyketone compounds.
1. A pharmaceutical liposomal composition comprising:
an aqueous solution comprising liposomes; and
the liposomes comprising
(i) between about 0.5 wt. % and about 50 wt. % of carfilzomib, wherein the carfilzomib is entrapped in the liposomes;
(ii) between about 99.5 wt. % and about 50 wt. % total lipids, wherein the total lipids comprise a phospholipid selected from the group consisting of L-α-phosphatidylcholine; 1,2-distearoyl-sn-glycero-3-phosphocholine; 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; 1,2-Distearoyl-sn-glycero-3-phospho-rac-(1-glycerol); 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; sphingomyelin; 1,2-distearoyl-sn-glycero-3-phosphoethanolamine; and combinations thereof;
wherein the liposomes have an average size of between about 0.05 microns and about 0.5 microns, and the carfilzomib is present in the composition in a concentration between 1 mg/ml and 2 mg/ml.
2. The pharmaceutical liposomal composition of claim 1 , wherein the phospholipid comprises L-α-phosphatidylcholine.
3. The pharmaceutical liposomal composition of claim 1 , wherein the total lipids comprise between about 30 wt. % and about 90 wt. % of the phospholipid.
4. The pharmaceutical liposomal composition of 1 , wherein the total lipids further comprise a hydrophilic polymer-derivatized lipid.
5. The pharmaceutical liposomal composition of claim 4 , wherein the total lipids comprise between about 8 wt. % and about 20 wt. % of the hydrophilic polymer-derivatized lipid.
6. The pharmaceutical liposomal composition of claim 4 , wherein the hydrophilic polymer-derivatized lipid comprises a hydrophilic polymer and a lipid, and the hydrophilic polymer is a polyethylene glycol.
7. The pharmaceutical liposomal composition of claim 6 , wherein the lipid of the hydrophilic polymer-derivatized lipid is cholesterol or a phospholipid.
8. The pharmaceutical liposomal composition of claim 1 , wherein the total lipids further comprise a cholesterol or cholesterol derivative.
9. The pharmaceutical liposomal composition of claim 8 , wherein the total lipids comprise between about 15 wt. % and about 30 wt. % of the cholesterol or cholesterol derivative.
10. The pharmaceutical liposomal composition of claim 8 , wherein the total lipids further comprise a hydrophilic polymer-derivatized lipid.
11. The pharmaceutical liposomal composition of claim 10 , wherein the total lipids comprise between about 83.3 wt. % of the phospholipid and about 57 wt. % of the phospholipid, between about 8.33 wt. % of the hydrophilic polymer-derivatized lipid and about 14 wt. % of the hydrophilic polymer-derivatized lipid, and between about 8.33 wt. % of the cholesterol or cholesterol derivative and about 29 wt. % of the cholesterol or cholesterol derivative.
12. The pharmaceutical liposomal composition of claim 1 , comprising between about 1 wt. % and about 25 wt. % carfilzomib, and between about 99 wt. % and about 75 wt. % of the total lipids.
13. The pharmaceutical liposomal composition of claim 1 , wherein the average size of the liposomes is selected from the group consisting of: between about 0.05 microns and about 0.15 microns; and between about 0.05 microns and about 0.10 microns.
14. The pharmaceutical liposomal composition of claim 1 , wherein the liposomes comprises carfilzomib and a solubilizing agent in an internal aqueous core of the liposomes.
15. The pharmaceutical liposomal composition of claim 14 , wherein the solubilizing agent is sulfobutylether-betacyclodextrin, and the liposomes of the liposomal composition comprise carfilzomib complexed with the cyclodextrin in the internal aqueous core of the liposomes.
16. A pharmaceutically acceptable liposome comprising:
(i) between about 0.5 wt. % and about 50 wt. % carfilzomib; and
(ii) between about 99.5 wt. % and about 50 wt. % total lipids, wherein the total lipids comprise a phospholipid selected from the group consisting of L-α-phosphatidylcholine; 1,2-distearoyl-sn-glycero-3-phosphocholine; 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; 1,2-Distearoyl-sn-glycero-3-phospho-rac-(1-glycerol); 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; sphingomyelin; 1,2-distearoyl-sn-glycero-3-phosphoethanolamine; and combinations thereof.
17. The pharmaceutically acceptable liposome of claim 16 , wherein the total lipids comprise between about 30 wt. % and about 90 wt. % of the phospholipid.
18. The pharmaceutically acceptable liposome of claim 16 , wherein the total lipids further comprise a hydrophilic polymer-derivatized lipid.
19. The pharmaceutically acceptable liposome of claim 16 , wherein the total lipids further comprise a cholesterol or cholesterol derivative.
20. The pharmaceutically acceptable liposome of claim 16 , wherein the total lipids comprise between about 83.3 wt. % of the phospholipid and about 57 wt. % of the phospholipid, between about 8.33 wt. % of a hydrophilic polymer-derivatized lipid and about 14 wt. % of a hydrophilic polymer-derivatized lipid, and between about 8.33 wt. % of a cholesterol or cholesterol derivative and about 29 wt. % of the cholesterol or cholesterol derivative.
21. The pharmaceutically acceptable liposome of claim 16 , comprising between about 1 wt. % and about 25 wt. % of carfilzomib, and between about 99 wt. % and about 75 wt. % of the total lipids.
22. The pharmaceutically acceptable liposome of claim 16 , further comprising sulfobutylether-betacyclodextrin.
23. The pharmaceutically acceptable liposome of claim 16 , further comprising one or more additional excipients selected from the group consisting of a cryoprotectant agent, a sugar, a glass transition modifying agent selected from the group consisting of a sugar, a polyol, a polymer, an amino acid, and combinations thereof, and a combination of any of the foregoing.
24. A method of treating multiple myeloma in a subject in need of treatment, comprising:
administering a therapeutically effective amount of a pharmaceutical liposomal composition of claim 1 to the subject.
25. The method of claim 24 , further comprising simultaneous, sequential, or separate administration of a therapeutically effective amount of a chemotherapeutic agent, a cytokine, a steroid, or an immunotherapeutic agent.
26. The pharmaceutical liposomal composition of claim 1 , wherein the carfilzomib is present in the composition in a concentration of 2 mg/ml.